{
    "patient": {
        "Name": "Michael Bennett",
        "DateOfBirth": "1966-07-03",
        "Sex": "Female",
        "Diagnosis": "Adenocarcinoma",
        "BodyPart": "Prostate",
        "Physician": "Dr. Michelle Wilson",
        "TreatingInstitution": "Jones, Obrien and Williams"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Prostate",
            "CollectedDate": "2023-12-23",
            "ReceivedDate": "2023-12-23",
            "TumorPercentage": "78%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-12-24",
            "ReceivedDate": "2023-12-24"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.101G>T",
                "GeneMutation": "p.T41I Stopgain-LOF",
                "VariantAlleleFraction": "20.35%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.395G>T",
                "GeneMutation": "p.S45P Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.96%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.1848_1849delinsCT",
                "GeneMutation": "p.S37C Spliceregionvariant-LOF",
                "VariantAlleleFraction": "12.16%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.3587G>A",
                "GeneMutation": "p.R132L Spliceregionvariant-LOF",
                "VariantAlleleFraction": "17.91%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1544G>T",
                "GeneMutation": "p.T875N Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "8.17%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": []
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "33 m/Mb",
            "Tmbpercentile": "8%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    }
}